Cargando…

The role of glutamine metabolism in castration-resistant prostate cancer

Reprogramming of metabolism is a hallmark of tumors, which has been explored for therapeutic purposes. Prostate cancer (PCa), particularly advanced and therapy-resistant PCa, displays unique metabolic properties. Targeting metabolic vulnerabilities in PCa may benefit patients who have exhausted curr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Bing, Wang, Jing, Chen, Li, Wang, Hong, Liang, Chao-Zhao, Huang, Jiaoti, Xu, Ling-Fan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2023
Materias:	Invited Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10069699/ https://www.ncbi.nlm.nih.gov/pubmed/36629158 http://dx.doi.org/10.4103/aja2022105

Ejemplares similares

Transcriptional repression by androgen receptor: roles in castration-resistant prostate cancer
por: Gritsina, Galina, et al.
Publicado: (2019)

Prostate cancer: molecular and cellular mechanisms and their implications in therapy resistance and disease progression
por: Feng, Ninghan, et al.
Publicado: (2019)

Optimal treatment for castration-resistant prostate cancer
por: Izumi, Kouji, et al.
Publicado: (2014)

Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014)

New developments in the treatment of castration resistant prostate cancer
por: Wadia, Roxanne, et al.
Publicado: (2014)

Serum lipid profiles and aggressive prostate cancer
por: Li, Yanjing, et al.
Publicado: (2015)

Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer
por: Stein, Mark N, et al.
Publicado: (2014)

Current opinion and mechanistic interpretation of combination therapy for castration-resistant prostate cancer
por: Xu, Jin, et al.
Publicado: (2019)

Reappraisal of glucocorticoids in castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014)

Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer
por: Markowski, Mark C, et al.
Publicado: (2015)

Targeting Glutamine Metabolism for Cancer Treatment
por: Choi, Yeon-Kyung, et al.
Publicado: (2018)

PD-1 inhibitor plus anlotinib for metastatic castration-resistant prostate cancer: a real-world study
por: Du, Xin-Xing, et al.
Publicado: (2022)

The metastatic castration-resistant prostate cancer treatment paradigm: more choices, more questions
por: Yu, Evan Y, et al.
Publicado: (2014)

Targeted prostate biopsy: value of multiparametric magnetic resonance imaging in detection of localized cancer
por: Le, Jesse D, et al.
Publicado: (2014)

What is the next generation therapeutic strategy for castration-resistant prostate cancer
por: Wen, Si-Meng, et al.
Publicado: (2015)

More evidence intratumoral DHT synthesis drives castration-resistant prostate cancer
por: Wilson, Elizabeth M
Publicado: (2014)

Enzalutamide in chemo-naïve castration-resistant prostate cancer: effective for most but not for all
por: Maughan, Benjamin L, et al.
Publicado: (2014)

Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy?
por: Merseburger, Axel S., et al.
Publicado: (2014)

Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer
por: Luo, Jun
Publicado: (2016)

Dexamethasone use in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: this “cort” is not out of order!
por: Van Praet, Charles, et al.
Publicado: (2021)

Androgen receptor variant-7: an important predictive biomarker in castrate resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2015)

Darolutamide: a novel androgen-signaling agent in nonmetastatic castration-resistant prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2019)

New therapies for relapsed castration-resistant prostate cancer based on peptide analogs of hypothalamic hormones
por: Schally, Andrew V, et al.
Publicado: (2015)

Androgen-deprivation therapy-induced aggressive prostate cancer with neuroendocrine differentiation
por: Lipianskaya, Julia, et al.
Publicado: (2014)

Further analysis of PREVAIL: enzalutamide use in chemotherapy-naïve men with metastatic castration-resistant prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2014)

Fasting times in serum PSA assay
por: Xu, Xiang, et al.
Publicado: (2014)

Glutamine and Cholesterol Plasma Levels and Clinical Outcomes of Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Taxanes
por: Marín-Aguilera, Mercedes, et al.
Publicado: (2021)

Non-Coding RNAs in Castration-Resistant Prostate Cancer: Regulation of Androgen Receptor Signaling and Cancer Metabolism
por: Shih, Jing-Wen, et al.
Publicado: (2015)

Identification of castration-dependent and -independent driver genes and pathways in castration-resistant prostate cancer (CRPC)
por: Li, Yan, et al.
Publicado: (2022)

A Five Glutamine-Associated Signature Predicts Prognosis of Prostate Cancer and Links Glutamine Metabolism with Tumor Microenvironment
por: Wang, Hai, et al.
Publicado: (2023)

Nonmetastatic Castration-Resistant Prostate Cancer
por: Hong, Jun Hyuk, et al.
Publicado: (2014)

SQLE Mediates Metabolic Reprogramming to Promote LN Metastasis in Castration-Resistant Prostate Cancer
por: Xu, Zhenzhou, et al.
Publicado: (2021)

Lineage plasticity-mediated therapy resistance in prostate cancer
por: Blee, Alexandra M, et al.
Publicado: (2019)

Molecular and cellular mechanisms of castration resistant prostate cancer
por: Huang, Yiqiao, et al.
Publicado: (2018)

The tumor suppressive role of CAMK2N1 in castration-resistant prostate cancer
por: Wang, Tao, et al.
Publicado: (2014)

The role of mRNA splicing in prostate cancer
por: Lapuk, Anna V, et al.
Publicado: (2014)

Nerve growth factor interacts with CHRM4 and promotes neuroendocrine differentiation of prostate cancer and castration resistance
por: Chen, Wei-Yu, et al.
Publicado: (2021)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

Role of chemotherapy in prostate cancer
por: Nader, Rita, et al.
Publicado: (2018)

Mutant allele quantification reveals a genetic basis for TP53 mutation-driven castration resistance in prostate cancer cells
por: Lei, Kefeng, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ot7bhdsf5qkig9suor777q3tii